All Press Releases | Biogen Media

All Press Releases

Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair
4/14/15 4:05 pm EDT
Biogen Data at AAN Annual Meeting Underscore Commitment to Advancing Patient Care in Neurology
4/7/15 7:30 am EDT
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS
3/27/15 7:00 am EDT
Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference
3/20/15 5:35 am EDT
Biogen Idec, Columbia University and HudsonAlpha Institute Identify New ALS Gene and Signaling Pathways
2/19/15 2:05 pm EST
Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals
10/15/14 8:00 am EDT
Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)
9/12/14 7:30 am EDT
New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients
9/11/14 7:30 am EDT
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms
9/10/14 7:00 am EDT
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
8/15/14 6:32 pm EDT